JP7059179B2 - 遺伝子操作のための方法及び製品 - Google Patents

遺伝子操作のための方法及び製品 Download PDF

Info

Publication number
JP7059179B2
JP7059179B2 JP2018520155A JP2018520155A JP7059179B2 JP 7059179 B2 JP7059179 B2 JP 7059179B2 JP 2018520155 A JP2018520155 A JP 2018520155A JP 2018520155 A JP2018520155 A JP 2018520155A JP 7059179 B2 JP7059179 B2 JP 7059179B2
Authority
JP
Japan
Prior art keywords
virus
derived
particles
protein
cas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018520155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531023A5 (fr
JP2018531023A6 (ja
JP2018531023A (ja
Inventor
オールマン，テオフィル
マンジョ，フィリップ
リッチ，エミリアーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2018531023A publication Critical patent/JP2018531023A/ja
Publication of JP2018531023A6 publication Critical patent/JP2018531023A6/ja
Publication of JP2018531023A5 publication Critical patent/JP2018531023A5/ja
Priority to JP2021212300A priority Critical patent/JP2022046680A/ja
Application granted granted Critical
Publication of JP7059179B2 publication Critical patent/JP7059179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2018520155A 2015-10-20 2016-10-20 遺伝子操作のための方法及び製品 Active JP7059179B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021212300A JP2022046680A (ja) 2015-10-20 2021-12-27 遺伝子操作のための方法及び製品

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306678.2 2015-10-20
EP15306678 2015-10-20
PCT/EP2016/075289 WO2017068077A1 (fr) 2015-10-20 2016-10-20 Méthodes et produits pour génie génétique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021212300A Division JP2022046680A (ja) 2015-10-20 2021-12-27 遺伝子操作のための方法及び製品

Publications (4)

Publication Number Publication Date
JP2018531023A JP2018531023A (ja) 2018-10-25
JP2018531023A6 JP2018531023A6 (ja) 2018-12-13
JP2018531023A5 JP2018531023A5 (fr) 2019-11-28
JP7059179B2 true JP7059179B2 (ja) 2022-04-25

Family

ID=55024029

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018520155A Active JP7059179B2 (ja) 2015-10-20 2016-10-20 遺伝子操作のための方法及び製品
JP2021212300A Pending JP2022046680A (ja) 2015-10-20 2021-12-27 遺伝子操作のための方法及び製品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021212300A Pending JP2022046680A (ja) 2015-10-20 2021-12-27 遺伝子操作のための方法及び製品

Country Status (3)

Country Link
US (3) US10968253B2 (fr)
JP (2) JP7059179B2 (fr)
WO (1) WO2017068077A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046680A (ja) * 2015-10-20 2022-03-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子操作のための方法及び製品

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (fr) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Vecteurs lentiviraux sûrs pour une administration ciblée de multiples molécules thérapeutiques
EP3613852A3 (fr) 2011-07-22 2020-04-22 President and Fellows of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2017007994A1 (fr) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Pré-immunisation et immunothérapie du vih
CN108513575A (zh) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 核碱基编辑器及其用途
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN108883100B (zh) 2016-01-15 2022-11-25 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
WO2017139065A1 (fr) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Vaccination et immunothérapie contre le vih
EP3426777B1 (fr) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Vecteurs de combinaison et méthodes de traitement du cancer
EP3468617A4 (fr) 2016-06-08 2020-01-22 American Gene Technologies International Inc. Système d'administration viral sans intégration et procédés associés à ce dernier
WO2018009246A1 (fr) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Pré-immunisation et immunothérapie du vih
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
WO2018027078A1 (fr) 2016-08-03 2018-02-08 President And Fellows Of Harard College Éditeurs de nucléobases d'adénosine et utilisations associées
CA3033327A1 (fr) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Proteines de fusion cas9-recombinase programmables et utilisations associees
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (fr) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression de la douleur par édition de gène
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
CN110785179A (zh) * 2017-04-21 2020-02-11 西雅图儿童医院（Dba西雅图儿童研究所） Wiskott-Aldrich综合征和X连锁血小板减少症中的治疗性基因组编辑
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
JP2019198250A (ja) * 2018-05-14 2019-11-21 石原産業株式会社 ゲノム編集用キット
CA3105925A1 (fr) * 2018-07-10 2020-01-16 Alia Therapeutics S.R.L. Vesicules pour l'administration sans trace de molecules d'arn de guidage et/ou d'un complexe de nuclease guide par une molecule d'arn guide (es) et son procede de production
US20210269790A1 (en) * 2018-07-13 2021-09-02 Kyoto University Virus-like particles and use thereof
KR20200011899A (ko) * 2018-07-25 2020-02-04 주식회사 툴젠 인위적인 유전자 조작을 통한 자가면역질환 치료
US20220088224A1 (en) 2018-09-18 2022-03-24 Vnv Newco Inc. Arc-based capsids and uses thereof
JP2022506515A (ja) 2018-11-05 2022-01-17 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 制御性ｒｎａを発現させるためのベクターシステム
EP3877398A4 (fr) * 2018-11-08 2022-08-17 Arizona Board of Regents on behalf of Arizona State University Immunomodulation synthétique avec un super-répresseur de crispr in vivo
US20230193255A1 (en) * 2018-11-16 2023-06-22 The Regents Of The University Of California Compositions and methods for delivering crispr/cas effector polypeptides
WO2020160418A1 (fr) * 2019-01-31 2020-08-06 Board Of Regents Of The University Of Nebraska Particules pseudovirales et leurs procédés d'utilisation
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
CN114258398A (zh) * 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
WO2021030165A1 (fr) 2019-08-09 2021-02-18 University Of Utah Research Foundation Ligand chimio-optogénétique à fonction étagée "trpswitch"
US20220333132A1 (en) 2019-09-03 2022-10-20 Sana Blotechnology, Inc. Cd24-associated particles and related methods and uses thereof
WO2021050593A1 (fr) 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions et méthodes pour le ciblage de sod1
WO2021050601A1 (fr) * 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions et procédés destinés à être utilisés en immunothérapie
WO2021055855A1 (fr) * 2019-09-20 2021-03-25 The Broad Institute, Inc. Compositions et procédés d'administration de charge à une cellule cible
EP4041867A1 (fr) 2019-10-09 2022-08-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Lymphocytes t modifiés pour exprimer cxcr4 muté ou partiellement supprimés et leurs utilisations
WO2021113763A1 (fr) * 2019-12-06 2021-06-10 Scribe Therapeutics Inc. Compositions et méthodes pour le ciblage de la rhodopsine
EP4069716A1 (fr) * 2019-12-06 2022-10-12 Scribe Therapeutics Inc. Systèmes d'administration de particules
EP4069846A1 (fr) * 2019-12-07 2022-10-12 Scribe Therapeutics Inc. Compositions et méthodes pour le ciblage de htt
EP4146804A1 (fr) 2020-05-08 2023-03-15 The Broad Institute Inc. Méthodes et compositions d'édition simultanée des deux brins d'une séquence nucléotidique double brin cible
US20220403379A1 (en) * 2021-05-28 2022-12-22 The Regents Of The University Of California Compositions and methods for targeted delivery of crispr-cas effector polypeptides and transgenes
IL308836A (en) 2021-05-28 2024-01-01 Sana Biotechnology Inc Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses
WO2022261149A2 (fr) * 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Systèmes d'administration de particules
WO2023077107A1 (fr) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Procédés et réactifs pour amplifier des produits d'acide nucléique de vecteur viral
CA3238778A1 (fr) * 2021-12-03 2023-06-08 David R. Liu Particules de type virus a auto-assemblage pour administration de proteines de fusion programmables par acide nucleique et leurs methodes de fabrication et d'utilisation
WO2023102538A1 (fr) * 2021-12-03 2023-06-08 The Broad Institute, Inc. Particules pseudovirales auto-assemblées pour administration d'éditeurs principaux et procédés de fabrication et d'utilisation de ces dernières
WO2023102550A2 (fr) * 2021-12-03 2023-06-08 The Broad Institute, Inc. Compositions et méthodes pour administration in vivo efficace
WO2023114949A1 (fr) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Procédés et systèmes de production de particules
TW202342757A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科附著醣蛋白
TW202342498A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科融合醣蛋白
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2023150518A1 (fr) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Vecteurs lentiviraux ciblant cd3 et leurs utilisations
WO2023150647A1 (fr) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Procédés d'administration et de dosage répétés de particules lipidiques ou de vecteurs viraux et systèmes et utilisations connexes
WO2024026377A1 (fr) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Procédés de transduction utilisant un vecteur viral et des inhibiteurs de facteurs de restriction antiviraux
WO2024044655A1 (fr) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Administration de protéines hétérologues
WO2024064838A1 (fr) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Particules lipidiques comprenant des glycoprotéines fixant des paramyxovirus variants et leurs utilisations
WO2024081820A1 (fr) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Particules virales ciblant des cellules souches hématopoïétiques
WO2024119157A1 (fr) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014131833A1 (fr) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Édition de gène dans l'ovocyte au moyen de cas9 nucléases
WO2014200659A1 (fr) 2013-06-11 2014-12-18 Clontech Laboratories, Inc. Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation
JP2015505299A (ja) 2011-11-11 2015-02-19 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法
JP2015523856A (ja) 2012-05-25 2015-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフ Ｒｎａ依存性標的ｄｎａ修飾およびｒｎａ依存性転写調節のための方法および組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
GB9227068D0 (en) 1992-12-29 1993-02-24 British Bio Technology Novel proteinaceous particles
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
EP1141313A2 (fr) * 1998-12-31 2001-10-10 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
WO2010040023A2 (fr) * 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Méthodes et compositions d’administration de protéines
US20110262483A1 (en) * 2008-11-03 2011-10-27 Ligocyte Pharmaceuticals, Inc. Methods for isolating enveloped virus-based vlps free of infectious agents
DE102010025907A1 (de) 2010-07-02 2012-01-05 Robert Bosch Gmbh Wellenenergiewandler zur Umwandlung von kinetischer Energie in elektrische Energie
EP3597741A1 (fr) 2012-04-27 2020-01-22 Duke University Correction génétique de gènes ayant subi une mutation
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分***、方法以及组合物
EP3971287A1 (fr) * 2013-07-11 2022-03-23 ModernaTX, Inc. Compositions comprenant des polynucléotides synthétiques codant pour des protéines liées à crispr et des arnsg synthétiques et méthodes d'utilisation
JP2016539998A (ja) 2013-12-12 2016-12-22 ダウ アグロサイエンシィズ エルエルシー ハラウキシフェンによる選択的雑草防除
EP3080271B1 (fr) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systèmes, procédés et compositions pour manipulation de séquences avec systèmes crispr-cas fonctionnels optimisés
CN111206032A (zh) * 2013-12-12 2020-05-29 布罗德研究所有限公司 用于基因组编辑的crispr-cas***和组合物的递送、用途和治疗应用
BR112016028023A2 (pt) * 2014-05-30 2017-08-22 Univ Leland Stanford Junior Composições e métodos de administração de tratamentos para infecções virais latentes
EP3189138A4 (fr) * 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Procédés et compositions pour atténuer des réponses immunitaires contre des vecteurs de transfert viraux pour l'édition génique
CN107406838A (zh) * 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
WO2017068077A1 (fr) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Méthodes et produits pour génie génétique
EP3389700B1 (fr) * 2015-12-17 2020-11-04 The Penn State Research Foundation Particules pseudovirales de paramyxovirus en tant que véhicules d'administration de protéine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505299A (ja) 2011-11-11 2015-02-19 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法
JP2015523856A (ja) 2012-05-25 2015-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフ Ｒｎａ依存性標的ｄｎａ修飾およびｒｎａ依存性転写調節のための方法および組成物
WO2014131833A1 (fr) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Édition de gène dans l'ovocyte au moyen de cas9 nucléases
WO2014200659A1 (fr) 2013-06-11 2014-12-18 Clontech Laboratories, Inc. Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAI, Y., et al.，"Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases."，eLife，2014年，Vol. 3，e01911(pp.1-19)，DOI:10.7554/elife.01911
HORII, T., et al.，"Efficient generation of knockin mice by CRISPR/Cas system."，Exp. Anim.，2015年，vol.64, supplement，p.S31(O-7)
KABADI, A.M., et al.，"Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector."，Nucleic Acids Research，2014年，Vol. 42, No. 19，e147，Published online 13 August 2014, doi: 10.1093/nar/gku749
KIM, S., et al.，"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins."，Genome Res.，2014年，vol.24, no.6，p.1012-1019, Supplemental Information

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046680A (ja) * 2015-10-20 2022-03-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子操作のための方法及び製品

Also Published As

Publication number Publication date
US20190055288A1 (en) 2019-02-21
US11649264B2 (en) 2023-05-16
US10968253B2 (en) 2021-04-06
US20210284697A1 (en) 2021-09-16
US20240109940A1 (en) 2024-04-04
JP2018531023A (ja) 2018-10-25
JP2022046680A (ja) 2022-03-23
US20240132547A1 (en) 2024-04-25
WO2017068077A1 (fr) 2017-04-27

Similar Documents

Publication Publication Date Title
JP7059179B2 (ja) 遺伝子操作のための方法及び製品
JP2018531023A6 (ja) 遺伝子操作のための方法及び製品
US20210139872A1 (en) Crispr having or associated with destabilization domains
US11459557B2 (en) Use and production of CHD8+/− transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
EP3356520B1 (fr) Système lentivirale de distribution de protéines guidée par l'édition de l'arn du génome
JP2021530985A (ja) フソソームの組成物及びその使用
WO2018005873A1 (fr) Systèmes crispr-cas ayant un domaine de déstabilisation
CA3120282A1 (fr) Compositions de fusosomes pour l'apport de cellules souches hematopoietiques
EP3230451A1 (fr) Arn guides protégés (pgrnas)
JP2017527256A (ja) ＨＢＶ及びウイルス性疾患及び障害のためのＣＲＩＳＰＲ−Ｃａｓ系及び組成物の送達、使用及び治療適用
US20210353543A1 (en) Targeted lipid particles and compositions and uses thereof
US11492614B2 (en) Stem loop RNA mediated transport of mitochondria genome editing molecules (endonucleases) into the mitochondria
CA3188810A1 (fr) Procedes et compositions pour produire des fusosomes viraux
US20240228546A9 (en) Methods and products for genetic engineering
CA3214277A1 (fr) Compositions a base de transposons ltr et procedes
EP3365437A1 (fr) Méthodes et produits pour génie génétique
WO2023150647A1 (fr) Procédés d'administration et de dosage répétés de particules lipidiques ou de vecteurs viraux et systèmes et utilisations connexes
WO2024064838A1 (fr) Particules lipidiques comprenant des glycoprotéines fixant des paramyxovirus variants et leurs utilisations
Rasmussen et al. Complementarity between RNA dimerization elements favors formation of functional heterozygous murine leukemia viruses
JP2024514649A (ja) 肝細胞の遺伝子修飾
JP2023550381A (ja) 真核生物遺伝子編集のためのベクター、システムおよび方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211227

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220221

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220413

R150 Certificate of patent or registration of utility model

Ref document number: 7059179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150